BioLife Solutions (NASDAQ:BLFS – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.
Analyst Ratings
This is a summary of recent recommendations and price targets for BioLife Solutions and Champions Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLife Solutions | 0 | 10 | 1 | 0 | 2.09 |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
BioLife Solutions presently has a consensus target price of $31.38, suggesting a potential downside of 18.74%. Given BioLife Solutions’ stronger consensus rating and higher possible upside, equities research analysts plainly believe BioLife Solutions is more favorable than Champions Oncology.
Volatility and Risk
BioLife Solutions has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.
Profitability
This table compares BioLife Solutions and Champions Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLife Solutions | 53.29% | 2.70% | 2.49% |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
Institutional and Insider Ownership
93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 46.3% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares BioLife Solutions and Champions Oncology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioLife Solutions | $106.69 million | 17.71 | -$4.59 million | $1.16 | 33.28 |
| Champions Oncology | $59.42 million | 1.12 | -$1.17 million | ($0.08) | -59.88 |
Champions Oncology has lower revenue, but higher earnings than BioLife Solutions. Champions Oncology is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.
Summary
BioLife Solutions beats Champions Oncology on 12 of the 14 factors compared between the two stocks.
About BioLife Solutions
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
